Johnson & Johnson’s subsidiary Janssen has announced data from new analyses of its phase 3 clinical trial showing the benefit of the Xarelto (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with peripheral arterial disease (PAD) after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs.
Source: Drug Industry Daily